- Medicines and Healthcare products Regulatory Agency
- 14 December 2016
- Therapeutic area:
- Anaesthesia and intensive care, Immunology and vaccination, Immunosuppression and transplantation, Ophthalmology, Pain management and palliation, Radiology and imaging, and Respiratory disease and allergy
Coadministration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal suppression due to a pharmacokinetic interaction.
Advice for healthcare professionals:
- all clinicians who may prescribe or administer steroids to patients with HIV should be aware that concomitant use of a corticosteroid metabolised by cytochrome P450 3A (CYP3A) and a HIV-treatment-boosting agent may increase the risk of systemic corticosteroid-related adverse effects
- although these reactions are rarely reported, there is potential for this interaction to occur even with non-systemically administered steroid formulations, including intranasal, inhaled, and intra-articular routes
- coadministration of a HIV-treatment-boosting agent with a CYP3A-metabolised corticosteroid is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid-related reactions
- if coadministration is necessary, use of beclomethasone should be considered where possible—particularly for long-term use. Beclomethasone is less dependent on CYP3A metabolism and, although the risk of an interaction leading to adverse corticosteroid effects may not be completely removed, it may be lower
Pharmacokinetic boosters are agents that are used to inhibit the metabolism of other substances, thereby increasing or prolonging the action of these substances. Ritonavir and its structural analogue cobicistat, being inhibitors of the CYP3A subfamily, are boosting agents that prolong the action of some antiretroviral medicines.1
An EU-wide review has identified 8 cases worldwide (including 1 published report4) of adrenal suppression during treatment with a cobicistat-containing regimen (Stribild) and subsequent prescription of an inhaled, intranasal, or intra-articular corticosteroid.
Reported reactions were adrenal insufficiency, adrenal suppression, and Cushing’s syndrome. The corticosteroids involved were intranasal and inhaled fluticasone, oral budesonide, and intra-articular triamcinolone. From clinical trials, a further report of adrenal insufficiency was identified where epidural methylprednisolone had been used together with intranasal fluticasone.
Most reports involved long-term use of corticosteroids, ranging from 9 months to over 1 year—also a known risk factor for development of adrenal suppression.
Product information for cobicistat-containing products is being strengthened to: warn of the potential for systemic corticosteroid-related reactions occurring with concomitant use; highlight the need for monitoring of patients for these events during treatment; and to advise consideration of lower-risk alternatives where possible (particularly, inhaled or intranasal beclomethasone).
Beclomethasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely. However, the possibility of systemic effects with concomitant use of cobicistat cannot be excluded, and therefore caution and appropriate monitoring is still advised with the use of beclomethasone.
Product information for corticosteroids is also being updated to warn of the potential for the interaction, resulting in systemic corticosteroid-related effects. This update excludes, however, formulations intended for cutaneous use only because of limited evidence of an interaction with cobicistat.
Reports of corticosteroid related effects have been received concerning patients taking HIV-protease inhibitors boosted with ritonavir who were also given epidural, intra-articular, or intramuscular injections of triamcinolone. Up to 21 November 2016, 26 UK Yellow Card reports of an interaction with triamcinolone and ritonavir have been reported: 18 reactions of Cushing’s syndrome or cushingoid features, and 17 of adrenal suppression. Product information for injectable formulations that contain triamcinolone is being updated to warn about the interaction with ritonavir.
A separate EU review identified 2 reports of Cushing’s syndrome from interactions between ocular dexamethasone and ritonavir. The review also noted an increased risk of systemic adrenal effects occurring with both ocular and cutaneous use after intensive or long-term therapy, and also considered these factors to be a risk for interactions with ritonavir. Product information for dexamethasone ocular and cutaneous formulations is being updated with warnings about a potential interaction with CYP3A4 inhibitors, including ritonavir; warnings are already present in product information for dexamethasone administered via oral or parenteral routes.
Interactions are also expected to occur with other corticosteroids that are metabolised by CYP3A. Suspected adverse drug reactions, including interactions, should be reported to us on a Yellow Card.
Article citation: Drug Safety Update vol 10 issue 5, December 2016: 1.
Marzolini C, et al. Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J Antimicrob Chemother 2016; 71: 1755–58. ↩
Jakeman B, et al. Iatrogenic Cushing’s syndrome after triamcinolone plus ritonavir-boosted atazanavir. J Am Pharm Assoc 2015; 55: 193–97. ↩
Saberi P, et al. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Medicine 2013; 14: 519–29. ↩
Lewis J, et al. A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS 2014; 28: 2633–39. ↩
Published: 14 December 2016